1 ngwa (10 Vials)
| Nnweta: | |
|---|---|
| Ọnụọgụ: | |
▎ Nyochaa Thymosin Alpha-1
Thymosin Alpha-1 (Thymalfasin), polypeptide na-apụta n'okike na thymus nke mejupụtara amino acid 28 nwere ọrụ immunomodulatory. Ọ na-achịkwa ọrụ usoro ahụ ji alụso ọrịa ọgụ site n'ịkwalite nzaghachi mgbochi Th1 na ịkwalite ọdịiche na maturation nke mkpụrụ ndụ T. Thymosin Alpha-1 egosila ike ọgwụgwọ na ọrịa dị iche iche, gụnyere ịba ọcha n'anya B na C, AIDS, ọrịa isi immunodeficiency, na ọrịa cancer. Na mgbakwunye, ọ na-egosipụta mmetụta dị ukwuu n'ịkwalite nzaghachi ọgwụ mgbochi yana melite arụ ọrụ immunological. Uru ya dị na nchekwa dị elu, nnabata dị mma, yana ikike ịkwalite nchebe nke ahụ megide ọrịa na etuto ahụ site na usoro sistemu ahụ ji alụso ọrịa ọgụ, ọkachasị na-ejide uru ngwa ụlọ ọgwụ dị mkpa na ọnọdụ immunocompromised ma ọ bụ immunodysregulated.
▎ Ọdịdị Thymosin Alpha-1
Isi mmalite: PubChem |
Usoro: SDAAVDTSSEITTKDLKEKKEVVEEAEN Ụdị mkpụrụ ndụ: C 129H 215N 33O55 Ibu ibu: 3108.3 g/mol Nọmba CAS: 62304-98-7 PubChem CID: 16130571 Synonyms: Thymalfasin; Zadaxin |
▎ Thymosin Alpha-1 Nnyocha
Kedu ihe bụ Thymosin Alpha-1?
Thymosin Alpha-1 bụ polypeptide nke mejupụtara 28 amino asịd. O doro anya na ọ dị na thymus ma na-arụ ọrụ dị oke mkpa na ntozu oke na usoro dị iche iche nke mkpụrụ ndụ T.
Kedu ihe ndabere nyocha nke Thymosin Alpha-1?
Thymosin Alpha-1 bụ bioactive polypeptide dịpụrụ adịpụ ma sachaa site na mkpụrụ nke thymosin 5, nke nwere amino acid 28. Thymus bụ akụkụ dị mkpa nke usoro ahụ ji alụso ọrịa ọgụ, nke na-emepụta ihe dị iche iche na-achịkwa ọrụ mgbochi ọrịa, thymosin bụkwa otu n'ime ha. Site na nyocha miri emi nke ọrụ nke thymus, ndị mmadụ ejirila nwayọọ nwayọọ ghọta na ihe ndị na-arụ ọrụ n'ime ya nwere ike ịba uru maka ọgwụgwọ ọrịa dị iche iche.
Gịnị bụ usoro nke Thymosin Alpha-1?
Immunomodulation:
Thymosin Alpha-1 bụ ihe mgbanwe nzaghachi ndu nke nwere ike ịgbalite mkpụrụ ndụ dị iche iche na sistemu ahụ ji alụso ọrịa ọgụ. Ọ na-achịkwa ọrụ mgbochi site n'ịkwalite ọdịiche na maturation nke mkpụrụ ndụ T (Sjogren MH, 2004; Mao L, 2023). Kpọmkwem, Thymosin Alpha-1 nwere ike imetụta thymocytes site n'ịkwalite ọdịiche ha ma ọ bụ gbanwee ha ka ha bụrụ sel T na-arụ ọrụ.
Usoro mgbochi mkpali:
Na ọgwụgwọ COVID-19 oyi baa, Thymosin Alpha-1 na-eme ka mgbake sitere na oyi baa site na usoro mgbochi mkpali ya. Ọ nwere ike belata nzaghachi mkpali, kwalite mbelata nke COVID-19 ka oyi baa dị ka ahụ ọkụ na ike ọgwụgwụ, mee ka nnabata nke exudate dị mfe, ma mee ka mgbake sitere na oyi baa COVID-19 (Wang Z, 2023).
Kedu ka Thymalfasin si ebute apoptosis nke mkpụrụ ndụ tumo na ọgwụgwọ ọrịa kansa?
Ịkwalite ọrụ nke sel ndị na-alụso ọrịa ọgụ:
Thymalfasin bụ thymopeptide sịntetik nwere ọrụ na-eme ka ahụ ike dị elu. Ọ nwere ike ịkwalite mmetụta igbu mmadụ nke mkpụrụ ndụ na-alụso ọrịa ọgụ na mkpụrụ ndụ tumo, si otú ahụ na-ebute apoptosis nke mkpụrụ ndụ etuto na-apụtaghị ìhè. Dịka ọmụmaatụ, na microenvironment tumor, Thymalfasin nwere ike ịkwalite ọdịiche na maturation nke mkpụrụ ndụ T ma kwalite ọrụ nke mkpụrụ ndụ T. Dị ka akụkụ dị mkpa nke usoro ahụ ji alụso ọrịa ọgụ, mkpụrụ ndụ T nwere ike ịmata ma wakpo mkpụrụ ndụ tumor, na-ebute apoptosis nke mkpụrụ ndụ tumo site na ịhapụ ihe cytotoxic na ụzọ ndị ọzọ.
Na-ahazi nzaghachi mgbochi ọrịa:
Dị ka immunopotentiator, Thymalfasin nwere ike na-ahazi nzaghachi nke dịghịzi ahụ ma mee ka apoptosis nke mkpụrụ ndụ tumo. Ọ nwere ike ịkwalite nzaghachi mgbochi Th1. Mkpụrụ ndụ Th1 na-ezobe cytokines dị ka IFN-γ, nke nwere ike ime ihe na mkpụrụ ndụ tumo ma mee ka apoptosis ha pụta. Tụkwasị na nke ahụ, Thymalfasin nwekwara ike ịhazi ọrụ nke mkpụrụ ndụ ndị ọzọ na-alụso ọrịa ọgụ, dị ka ịkwalite ọrụ nke mkpụrụ ndụ NK. Mkpụrụ ndụ NK nwere ike igbu mkpụrụ ndụ tumor ozugbo ma mee ka apoptosis nke mkpụrụ ndụ tumo site na nzuzo cytokines na ụzọ ndị ọzọ [1].
Imeziwanye mgbochi immunosuppression n'oge ọgwụgwọ mgbochi tumor:
N'oge usoro ọgwụgwọ tumor, ndị ọrịa na-enwetakarị immunosuppression, nke ga-emetụta irè ọgwụgwọ tumor. Thymalfasin nwere ike melite immunosuppression nke a na-emepụta n'oge ọgwụgwọ ọrịa tumor, kwalite ikike nke usoro ahụ ji alụso ọrịa ọgụ ọgụ mkpụrụ ndụ tumo, ma si otú ahụ mee ka apoptosis nke mkpụrụ ndụ tumo. Dịka ọmụmaatụ, n'oge chemotherapy ma ọ bụ redio, usoro ahụ ji alụso ọrịa ọgụ ga-emebi ruo n'ókè ụfọdụ. Thymalfasin nwere ike ịkwalite mgbake na mmụba nke mkpụrụ ndụ na-alụso ọrịa ọgụ, meziwanye ọrụ nke usoro ahụ ji alụso ọrịa ọgụ, ma kwalite mmetụta igbu mmadụ na mkpụrụ ndụ tumo.

Thymosin alpha 1 nwere ọtụtụ ihe omume ndu.
Isi mmalite: PubMed [6]
Kedu ihe bụ ngwa Thymalfasin?
Ọrịa nje virus:
N'ihi mmetụta immunomodulatory ya, a na-ejikarị Thymosin Alpha-1 agwọ ọrịa nje. Dịka ọmụmaatụ, n'oge ọrịa COVID-19, o gosipụtala ezigbo nrụpụta ụlọ ọgwụ na ọgwụgwọ nke oyi oyi COVID-19. Nnyocha na-egosi na Thymosin Alpha-1 nwere ike igbochi ọganihu nke ọrịa COVID-19 na-emekarị ka ọ bụrụ oyi oyi siri ike site na usoro nchebe dị iche iche na-akwalite mgbochi na mgbochi mkpali [2] . Kpọmkwem, maka ndị ọrịa na-agwọ Thymosin Alpha-1, ọnụnọ ụlọ ọgwụ ahụ dị mkpụmkpụ nke ukwuu, akụkụ nke enyemaka nke mgbaàmà ndị metụtara oyi oyi (dị ka ahụ ọkụ na ike ọgwụgwụ) dị elu karịa nke ndị na-achịkwa, na mpaghara nke exudation mkpali nke CT gosipụtara dịkwa ntakịrị karịa nke ndị na-ahụ maka nchịkwa [2] . Na mgbakwunye, nyocha ụdị Cox multivariate gosiri na ndị ọrịa ji Thymosin Alpha-1 na ndị ọrịa na-eto eto nwere mgbanwe mgbanwe na-adịghị mma ngwa ngwa nke COVID-19 antigens [2] . Tα1 (isi ihe dị na Thymosin Alpha-1) mụbara ọnụ ọgụgụ cell CD4 + T na ndị ọrịa nwere nkwado ikuku oxygen dị ala na ntọala ngwa ngwa karịa ọgwụgwọ ọkọlọtọ, ma nwee ike rụọ ọrụ na ọgwụgwọ nke ndị ọrịa nọ n'ụlọ ọgwụ nwere hypoxemia na lymphopenia nke COVID-19 [3] kpatara..
Ọgwụgwọ ịba ọcha n'anya:
Thymosin Alpha-1 nwekwara mmetụta ụfọdụ na ọgwụgwọ nke ịba ọcha n'anya. Enwere ike iji ya dị ka monotherapy maka ịba ọcha n'anya B ma ọ bụ na-ejikọta ya na interferon α-2b maka ọgwụgwọ ịba ọcha n'anya C. Kpọmkwem, nchọpụta chọpụtara na na ọgwụgwọ nke ịba ọcha n'anya B, a na-enyocha irè Thymosin Alpha-1 na ule anọ nke ụlọ ọgwụ metụtara ndị ọrịa 195. N'ime otu n'ime ọmụmụ ihe ahụ, 9 n'ime ndị ọrịa 17 na-agwọ Thymosin Alpha-1 nwere ọrịa ịba ọcha n'anya B (HBV) DNA na ọnwa isii, ma e jiri ya tụnyere 10 n'ime ndị ọrịa 16 na-emeso interferon α-2b na 4 n'ime ndị ọrịa 15 na-achịkwa akụkọ ihe mere eme.
Ọgwụgwọ Adjuvant: Thymosin Alpha-1 na-ejikwa n'ọtụtụ ebe na ọgwụgwọ ọrịa kansa. Maka ndị ọrịa nwere ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) na ọrịa imeju, na ọgwụgwọ adjuvant, Thymosin Alpha-1 nwere ike imeziwanye ọnụego nlanarị (OS) (Mao L, 2023). Maka ndị ọrịa nwere NSCLC dị elu na-enweghị mgbagha, Thymosin Alpha-1 nwere ike belata lymphopenia na oyi baa nke sitere na radiotherapy na chemotherapy, na enwere usoro nke imeziwanye OS [4]..
Na-akwalite mgbochi tumor:
Ihe akaebe gara aga na-egosi na Thymosin Alpha-1 nwere ike gbanwee M2 polarization nke efferocytosis nke macrophages kpatara site n'ịgbalite axis TLR7/SHIP1, welie irè nke chemotherapy ọrịa cancer, ma kwalite mgbochi tumor site n'ịgbanwe ' etuto oyi' n'ime ' etuto dị ọkụ,' 202 L. Tụkwasị na nke ahụ, Thymosin Alpha-1 nwekwara mmetụta nchebe n'ibelata colitis nke ndị na-eme ihe na-enyocha ihe mgbochi (ICIs) na-eme ka ọ dịkwuo mma ma nwee ike ịkwalite nrụpụta ụlọ ọgwụ nke ICI [4] . Tα1 dị ka ọgwụgwọ adjuvant mgbe a gbasasịrị ọrịa cancer imeju nwere ike imeziwanye amụma nke ndị ọrịa nwere obere carcinoma hepatocellular. N'ime ọmụmụ ihe na-emeghachi azụ azụ, ndị ọrịa nwere obere carcinoma hepatocellular bụ ndị na-emeju imeju na-ekewa n'ime ìgwè abụọ, otu A (resection + Tα1) na otu B (naanị resection). Mgbe usoro mgbasa ozi nke ọnwa 47.0 gasịrị, 1-, 3-, na 5-afọ n'ozuzu nke lanarị na ọnụ ọgụgụ ndị na-adị ndụ na-adịghachi ndụ nke ndị ọrịa nọ n'ìgwè A dị elu karịa ndị nọ n'ìgwè B. Multivariate analysis gosiri na Tα1 bụ ihe na-emepụta ihe na-emepụta onwe ya maka ọnụ ọgụgụ ndụ zuru ezu na nlọghachi azụ na-enweghị ndụ [5]..
Iweghachi ọrụ mgbochi ọrịa yana nkwalite ọgwụ mgbochi:
Enwere ike iji Thymosin Alpha-1 na-emeso steeti immunocompromised na malignancies yana dị ka nkwalite nke nzaghachi ọgwụ mgbochi [4, 6] . Ọ nwere ike ịhazi usoro ahụ ji alụso ọrịa ọgụ ma kwalite ọrụ T cell, ma nwee ike ịnweta uru ụlọ ọgwụ maka ọrịa ndị na-adịghị arụ ọrụ ma ọ bụ na-adịghị arụ ọrụ dị ka ọrịa na-adịghị ala ala na ọrịa na-adịghị ala ala, ọrịa cancer, na ọgwụ mgbochi na-enweghị nzaghachi [4] . Nnyocha egosila na na sepsis siri ike, Thymosin Alpha-1 egosila na ọ na-eweghachi ọrụ mgbochi ma nyere aka belata ọnụ ọgụgụ ndị ọrịa na-anwụ [4]..
Na-egbochi ọrịa COVID-19 na nsogbu dị n'ime ndị ọrịa na-eme dialysis gbasara akụrụ:
A na-ahụta ndị ọrịa nwere ọrịa akụrụ ngwụcha (ESRD) na-anata hemodialysis (HD) dị ka ndị nwere ike ibute ọrịa SARS-CoV2 n'ihi ihe ndị dị ka ịka nká, ibu nsogbu, iji ọgwụ eme ihe, yana mkpa ịga ụlọ ọgwụ dialysis ugboro ugboro. Nnyocha mbụ egosila na Thymosin Alpha-1, dị ka onye na-akwado ọgwụ mgbochi influenza, nwere ike ịkwalite nzaghachi mgbochi nke ndị agadi (gụnyere ndị ọrịa HD) na ọgwụ mgbochi influenza ma belata ọrịa influenza. N'oge mmalite nke ọrịa COVID-19, ndị nchọpụta kwuru na iji Thymosin Alpha-1 na ndị ọrịa HD nwere ike ibelata ọnọdụ na ogo nke ọrịa COVID-19. Dị ka nke July 1, 2022, 254 ESRD / HD ndị ọrịa sitere na ụlọ ọrụ dialysis ise dị na Kansas City, Missouri gụnyere na ọmụmụ ihe, nke ndị ọrịa 194 na-ekewa n'ụzọ na-enweghị usoro n'ime otu A (ntụtụ subcutaneous nke 1.6mg Thymosin Alpha-1 ugboro abụọ n'izu maka izu 8) na otu B (òtù njikwa, na-enwetaghị Thymosin) Alpha-.
N'ikpeazụ, dị ka polypeptide nwere ọrụ immunomodulatory pụrụ iche, Thymosin Alpha-1 egosila ngwa nwere ike n'ọtụtụ akụkụ na ngalaba ahụike. N'ịgwọ ọrịa nje, ọ na-enwe mmetụta dị ukwuu na ọrịa ndị dị ka ịba ọcha n'anya B na COVID-19. Ọ bụghị naanị na ọ ga-eme ka nkwụsị nke mgbaàmà dịkwuo ngwa ngwa ma belata mbufụt kamakwa igbochi ọganihu nke ọrịa ahụ ma melite ọnụego mgbake nke ndị ọrịa. N'ihe gbasara ọgwụgwọ tumor, ọ nwere ike ime ka apoptosis nke mkpụrụ ndụ tumo site n'ọtụtụ ụzọ, welie mmetụta igbu egbu nke mkpụrụ ndụ na-alụso ọrịa ọgụ na mkpụrụ ndụ tumo, ma melite ọnọdụ immunosuppressive, na-egosi arụmọrụ dị mma na ọgwụgwọ ọrịa cancer dị iche iche dị ka ọrịa cancer akpa ume na ọrịa imeju.
Banyere Onye dere ya
Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.
Onye ode akwụkwọ akụkọ sayensị
Wang Z bụ onye nyocha nwere mmụta mmụta dị iche iche yana ahụmịhe mmekọrịta dị ukwuu n'ofe ụlọ ọrụ dị iche iche. Ihe gbasara nyocha ha gbasara mpaghara interdisciplinary dị ka Engineering, Spectroscopy, Chemistry, Dentistry, Oral Surgery & Medicine, na Physics. Ejikọtala Wang Z na ụlọ ọrụ na mahadum a ma ama, gụnyere Mahadum China Academy of Sciences (CAS), Mahadum Yunnan, Mahadum Peking, Mahadum Ugbo Hunan, Mahadum Shanghai Jiao Tong, na ọtụtụ ndị ọzọ. Ọrụ ha na-egosipụta nlebara anya siri ike na mmepụta ọhụrụ na imekọ ihe ọnụ, karịsịa na mpaghara metụtara ọkụ ụlọ ọrụ optoelectronic engineering, ngwa ahụike, na sayensị ihe dị elu. Site na mmekorita ya na ulo oru dika Jiangsu Provincial Research Center maka Light Industrial Optoelectronic Engineering & Technology na Air Force Military Medical University, Wang Z enyela aka na mmepe nke usoro ihe omuma na ngwa bara uru n'ubi ha. Edepụtara Wang Z n'akwụkwọ ntụaka [2].
▎ Okwu ndị dị mkpa
[1] Sjogren M H. Thymalfasin: onye na-akwalite usoro ahụ ji alụso ọrịa ọgụ maka ọgwụgwọ ọrịa imeju. Akwụkwọ akụkọ nke Gastroenterology na Hepatology, 2004,19 Suppl 6:S69-S72. DOI:10.1111/j.1440-1746.2004.03635.x
[2] Wang Z, Wang C, Fei X, et al. Usoro ọgwụgwọ Thymalfasin na-eme ka mmezigharị oyi baa COVID-19 dị ngwa site na usoro mgbochi mkpali[J]. Ka oyi baa, 2023,15 (1).DOI:10.1186/s41479-023-00116-6.
[3] Shehadeh F, Benitez G, Mylona EK, et al. Ọnwụnwa pilot nke Thymalfasin (Thymosin-α-1) iji gwọọ ndị ọrịa nọ n'ụlọ ọgwụ nwere Hypoxemia na Lymphocytopenia N'ihi Ọrịa Coronavirus 2019 [J]. Akwụkwọ akụkọ nke ọrịa na-efe efe, 2023,227 (2): 226-235.DOI: 10.1093/infdis/jiac362.
[4] Mao L. Thymosin alpha 1-Tigharịa ngwa ya sara mbara na oge immuno-oncology [J]. International Immunopharmacology, 2023,117.DOI:10.1016/j.intimp.2023.109952.
[5] He C, Peng W, Li C, et al. Thymalfasin, ọgwụgwọ adjuvant na-ekwe nkwa na obere carcinoma hepatocellular mgbe a gbasasịrị imeju [J]. Ọgwụ, 2017,96 (16).DOI:10.1097/MD.000000000006606.
[6] Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: Nlebanya n'uju nke akwụkwọ.[J]. Akwụkwọ akụkọ ụwa nke Virology, 2020,9 (5): 67-78.DOI: 10.5501/wjv.v9.i5.67.
[7] Tuthhill CW, Awad A, Parrigon M, et al. Nnwale nnwale nke Thymalfasin (Ta1) iji gbochie ọrịa covid-19 na ọrịa na-efe efe na ndị ọrịa dialysis gbasara akụrụ: Akụkọ mbido [J]. International Immunopharmacology, 2023,117.DOI:10.1016/j.intimp.2023.109950.
Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.
Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadoghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.